MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco.20.02220

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021

NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.

Weiss Brian D, Wolters Pamela L, Plotkin Scott R, Widemann Brigitte C, Tonsgard James H, Blakeley Jaishri, Allen Jeffrey C, Schorry Elizabeth, Korf Bruce, Robison Nathan J, Goldman Stewart, Vinks Alexander A, Emoto Chie, Fukuda Tsuyoshi, Robinson Coretta T, Cutter Gary, Edwards Lloyd, Dombi Eva, Ratner Nancy, Packer Roger, Fisher Michael J

Клиническое исследование II фазыСтатьяМногоцентровое исследованиеПоддержка правительства СШАПеревод в очереди

Аннотация

PURPOSE: Patients with neurofibromatosis type 1 (NF1) frequently develop plexiform neurofibromas (PNs), which can cause significant morbidity. We performed a phase II trial of the MAPK/ERK kinase inhibitor, mirdametinib (PD-0325901), in patients with NF1 and inoperable PNs. The primary objective was response rate based on volumetric magnetic resonance imaging analysis.

METHODS

Inclusion criteria included age ≥ 16 years and a PN that was either progressive or causing significant morbidity. First-dose pharmacokinetics were performed. Patients completed patient-reported outcome measures. Patients received mirdametinib by mouth twice a day at 2 mg/m2/dose (maximum dose = 4 mg twice a day) in a 3-week on/1-week off sequence. Each course was 4 weeks in duration. Evaluations were performed after four courses for the first year and then after every six courses. Patients could receive a maximum of 24 total courses.

RESULTS

Nineteen patients were enrolled, and all 19 received mirdametinib. The median age was 24 years (range, 16-39 years); the median baseline tumor volume was 363.8 mL (range, 3.9-5,161 mL). Eight of the 19 patients (42%) achieved a partial response of the target PN by course 12, and 10 (53%) had stable disease. One patient (5%) developed progressive disease at course 8. Significant and durable decreases were observed in pain ratings.

CONCLUSION

To our knowledge, this analysis represents the first characterization of the activity and pharmacokinetics of mirdametinib in patients with NF1 and PNs and is the first published response study for MAPK/ERK kinase inhibitors in adults with NF1 and PNs. Mirdametinib given at 2 mg/m2/dose (maximum dose, 4 mg) twice daily in a 3-week on/1-week off sequence resulted in a 42% partial response rate with preliminary evidence of reduction in pain.

Для цитирования: Weiss Brian D, Wolters Pamela L, Plotkin Scott R, Widemann Brigitte C, Tonsgard James H, Blakeley Jaishri, Allen Jeffrey C, Schorry Elizabeth, Korf Bruce, Robison Nathan J, Goldman Stewart, Vinks Alexander A, Emoto Chie, Fukuda Tsuyoshi, Robinson Coretta T, Cutter Gary, Edwards Lloyd, Dombi Eva, Ratner Nancy, Packer Roger, Fisher Michael J. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021. DOI: 10.1200/jco.20.02220.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.